15 brokerages give Privia Health Group a "Moderate Buy" rating, directors and institutional investors purchase shares, Q3 EPS of $0.03 misses $0.05 consensus estimate.
Privia Health Group (NASDAQ: PRVA) has received a consensus "Moderate Buy" rating from 15 brokerages, with an average 1-year price target of $24.79. Recent insider transactions include directors Adam Boehler and Thomas A. McCarthy purchasing shares, and institutional investors such as Canada Pension Plan Investment Board and Nisa Investment Advisors LLC have made investments in the company. Privia Health Group reported Q3 earnings of $0.03 EPS, missing the consensus estimate of $0.05 by $0.02, and revenue of $422.30 million.
August 18, 2024
3 Articles